- Home
- EMF vs AMRN Comparison
EMF vs AMRN Comparison
Compare EMF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMF | AMRN |
|---|---|---|
| Founded | 1987 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.7M | 339.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | EMF | AMRN |
|---|---|---|
| Price | $17.48 | $14.53 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 68.7K | ★ 79.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $11.14 | $0.39 |
| 52 Week High | $21.20 | $20.90 |
Technical Indicators
Market Signals| Indicator | EMF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 28.93 | 43.84 |
| Support Level | $16.13 | $13.63 |
| Resistance Level | $17.90 | $14.55 |
| Average True Range (ATR) | 0.45 | 0.80 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 0.00 | 22.16 |
Price Performance
Historical ComparisonAbout EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.